1,557 reports of this reaction
2.8% of all ABIRATERONE ACETATE reports
#5 most reported adverse reaction
THERAPY CESSATION is the #5 most commonly reported adverse reaction for ABIRATERONE ACETATE, manufactured by Janssen Biotech, Inc.. There are 1,557 FDA adverse event reports linking ABIRATERONE ACETATE to THERAPY CESSATION. This represents approximately 2.8% of all 56,299 adverse event reports for this drug.
Patients taking ABIRATERONE ACETATE who experience therapy cessation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPY CESSATION is a less commonly reported adverse event for ABIRATERONE ACETATE, but still significant enough to appear in the safety profile.
In addition to therapy cessation, the following adverse reactions have been reported for ABIRATERONE ACETATE:
The following drugs have also been linked to therapy cessation in FDA adverse event reports:
THERAPY CESSATION has been reported as an adverse event in 1,557 FDA reports for ABIRATERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPY CESSATION accounts for approximately 2.8% of all adverse event reports for ABIRATERONE ACETATE, making it a notable side effect.
If you experience therapy cessation while taking ABIRATERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.